| Active substance |
Thalidomide |
| Also known as |
N/A |
| Blood pressure |
No specific impact on blood pressure |
| Chemical name |
(RS)-2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione |
| Dosage (medical) |
Typically 100 to 300 mg per day, depending on the condition being treated |
| Dosage (sports) |
Not applicable |
| Effects |
Reduction of inflammation, modulation of immune response |
| Formula |
C13H10N2O4 |
| Half-life |
5 to 7 hours |
| Hepatotoxicity |
Low risk of hepatotoxicity |
| Lab Test |
Not specifically required for monitoring thalidomide itself but monitoring of complete blood counts and liver function tests are advised during treatment |
| Main action |
Immunomodulatory and anti-inflammatory effects |
| Side effects |
Teratogenicity (causes birth defects), peripheral neuropathy, deep vein thrombosis, risk of severe life-threatening human birth defects |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
50mg |
| Substance class |
Immunomodulatory drug |
| Trade name |
Thalomid |
| Use in sports |
None |
| Water Retention |
No significant water retention |
| Manufacturer |
Natco Pharmaceuticals Ltd. |
| Packing |
10 caps/blister |
